TORVANTA
Other · S&P 500 · data as of 2026-10-05

PTCT stock analysis: PTCT

PTCT (PTCT) is an S&P 500 company in Other. It grades weakest on profitability, momentum, value and growth.

The model's view of PTCT · subscribers

Where PTCT ranks among the 1,500 U.S. stocks the model scores each trading day, its expected return, the evidence for and against it, and whether the model portfolio holds it. The grades below describe the company's data; they are not the model's view.

See plans
What's happening with PTCT · updated 2026-10-05 · from prices and SEC filings

PTCT price performance

PTCT against the S&P 500, one year
+0%+20%+40%S&P 500 +18%PTCT +5%2025-09-292026-10-05
Year to date-16.2%S&P 500 +14.5% · behind by 30.7 pts
1 year-2.6%S&P 500 +17.0% · behind by 19.7 pts
3 years+186.7%S&P 500 +89.3% · ahead by 97.5 pts
5 years+74.3%S&P 500 +91.3% · behind by 17.0 pts

Total returns with dividends reinvested.

PTCT factor grades

Each grade compares PTCT with the rest of its sector (A+ best, F worst); the numbers behind it are shown with the typical figure for its peers.

D-ValueFCF yield -0.7% (industry 6.0%)
FGrowthRevenue growth -43% (industry +8%)EPS growth -108% (industry +10%)
C-ProfitabilityOperating margin 12.5% (industry 9.6%)
D+Momentum12-month change -3%From 52-wk high -29%

PTCT in plain numbers

PTCT key statistics

SectorOther
Industryn/a
IndexS&P 500
Market value$5.3B
Revenue growth (y/y)-43%
Free-cash-flow yield-0.7%
Dividend yieldn/a
Next earnings (expected)2026-11-03
Valuation measures
Market value$5.3B
Enterprise value$4.9B
Price / sales5.3x
EV / revenue4.8x
EV / EBITDA26.8x
Financial highlights
Revenue, last 12 months$1.0B
Net income, last 12 months-$38.4M
EPS, last 12 months (GAAP)$-0.58
Operating margin12.5%
Net margin-3.8%
Cash$1.0B
Total debt$591.0M
Free cash flow, last 12 months-$39.7M
Current ratio3.39x

Company figures from its latest SEC filings; market value and returns from end-of-day prices.

PTCT earnings trends

Revenue vs earnings
-$135.0M$192.8M$520.6M$848.3M$1.2BSep 2024 Revenue: $196.8MDec 2024 Revenue: $213.2MMar 2025 Revenue: $1.2BJun 2025 Revenue: $178.9MSep 2025 Revenue: $211.0MDec 2025 Revenue: $164.7MMar 2026 Revenue: $272.6MJun 2026 Revenue: $360.5MSep 2024 Net income: -$106.7MDec 2024 Net income: -$65.9MMar 2025 Net income: $866.6MJun 2025 Net income: -$64.8MSep 2025 Net income: $15.9MDec 2025 Net income: -$135.0MMar 2026 Net income: -$2.8MJun 2026 Net income: $83.5MSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Net margin: -54.2%Net margin: -30.9%Net margin: 73.7%Net margin: -36.3%Net margin: 7.5%Net margin: -82.0%Net margin: -1.0%Net margin: 23.2%-82%-4%74%■ Revenue ■ Net income ━ Net margin
Earnings per share$-1.7$1.3$4.2$7.1$10.0Sep 2024 EPS (GAAP, diluted): $-1.4Dec 2024 EPS (GAAP, diluted): $-0.9Mar 2025 EPS (GAAP, diluted): $10.0Jun 2025 EPS (GAAP, diluted): $-0.8Sep 2025 EPS (GAAP, diluted): $0.2Dec 2025 EPS (GAAP, diluted): $-1.7Mar 2026 EPS (GAAP, diluted): $-0.0Jun 2026 EPS (GAAP, diluted): $0.9Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026■ EPS (GAAP, diluted) Change from a year earlier: Mar 2026 -100%

From the company's 10-Q and 10-K filings with the SEC.

PTCT financials (from SEC filings)

Fiscal yearFY2021FY2022FY2023FY2024FY2025
Revenue$538.6M$698.8M$937.8M$806.8M$1.7B
Net income-$523.9M-$559.0M-$626.6M-$363.3M$682.6M
EPS (GAAP)$-7.42$-8.29$-8.36$-4.73$7.74
Free cash flow-$279.5M-$388.7M-$186.9M-$128.9M$702.3M

PTCT earnings history

ReportedEPS (GAAP)EPS y/yRevenue y/yStock vs S&P 500, 2 days
2026-07-30$0.92n/a+102%-11.1%
2026-05-07$-0.03-100%-77%+10.2%
2026-02-19$-1.67n/a-23%+2.1%
2026-01-12$-1.67n/a-23%-2.7%
2025-11-04$0.20n/a+7%+6.5%
2025-08-07$-0.83n/a-4%-12.3%

About PTCT

HeadquartersWarren, NJ
Industry (SEC code)Pharmaceutical Preparations
Fiscal year endsDecember 31
Incorporated inDE
Listed onNasdaq
FormerlyPTC THERAPEUTICS INC

From the company's SEC registration record.

Companies similar to PTCT

CompanyMarket valueP/ERevenue growthOperating margin12-month change
PTCT PTCT$5.3Bn/a-43%12.5%-3%
CWST CWST$5.3Bn/a+14%3.4%-9%compare
SAIC SAIC$5.3B14.8x-1%8.0%+27%compare
TFX TFX$5.3Bn/a-3%-11.6%-3%compare
LAUR LAUR$5.3B17.4x+18%24.4%+31%
PSMT PSMT$5.3B33.0x+10%4.5%+41%
SHC SHC$5.3B32.5x+8%n/a+16%

All Other stock ratings

Frequently asked questions

Is PTCT stock a buy?

Torvanta does not tell individuals what to buy. Its grades for PTCT are shown above. Subscribers see the model's rank, expected return and whether the model portfolio holds it. This is research, not a recommendation.

When does PTCT report earnings next?

Based on its filing history, Torvanta expects PTCT to report around 2026-11-03.

How has PTCT performed against the S&P 500?

Over the past year PTCT returned -2.6%, against +17.0% for the S&P 500, dividends reinvested.

See the model's view

Subscribers get the model's rank and expected return for every covered company, the reasoning behind each, and the Torvanta model portfolio's trades each trading day, sized and explained, at three risk levels.

See plans Or get the free weekly newsletter

Torvanta is research only - not investment advice and not a recommendation to buy or sell any security. Grades describe a company's reported data against its sector; they are not the model's view, change as data changes and can be wrong. Financial figures come from the company's SEC filings; returns include reinvested dividends. Past performance does not predict future results.

All stock ratings · Stock lists · AI stock research · Model portfolio · Research · Disclaimer